Home › Multiple Myeloma
Multiple Myeloma clinical trials recruiting in the U.S.
239 studies for Multiple Myeloma are recruiting participants at sites across the United States.
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
Cities with the most studies
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA42 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Edison, NJ22 studies
- Chicago, IL22 studies
- Washington, DC22 studies
- Seattle, WA22 studies
- Charlotte, NC21 studies
- Milwaukee, WI21 studies
- Miami, FL21 studies
- Salt Lake City, UT21 studies
- Queens, NY20 studies
- Detroit, MI19 studies
- Birmingham, AL18 studies
- Jacksonville, FL18 studies
- Cincinnati, OH17 studies
- Los Angeles, CA17 studies
- Dallas, TX17 studies
- Philadelphia, PA16 studies
- Phoenix, AZ16 studies
- Omaha, NE16 studies
- Cleveland, OH16 studies
- San Francisco, CA15 studies
- Tampa, FL15 studies
- Cedar Rapids, IA15 studies
- Clifton, NJ14 studies
- New Haven, CT14 studies
- Winston-Salem, NC14 studies
- New Rochelle, NY14 studies
- Irvine, CA14 studies
- Indianapolis, IN13 studies
- Tacoma, WA13 studies
By state
- Alabama22 studies
- Arizona28 studies
- Arkansas9 studies
- California70 studies
- Colorado37 studies
- Connecticut18 studies
- Delaware4 studies
- District of Columbia10 studies
- Florida55 studies
- Georgia50 studies
- Idaho3 studies
- Illinois31 studies
- Indiana19 studies
- Iowa17 studies
- Kansas12 studies
- Kentucky15 studies
- Louisiana9 studies
- Maine3 studies
- Maryland25 studies
- Massachusetts44 studies
- Michigan26 studies
- Minnesota30 studies
- Missouri27 studies
- Montana5 studies
- Nebraska18 studies
- New Hampshire4 studies
- New Jersey38 studies
- New Mexico5 studies
- New York75 studies
- North Carolina52 studies
- North Dakota5 studies
- Ohio46 studies
- Oklahoma3 studies
- Oregon20 studies
- Pennsylvania23 studies
- Rhode Island6 studies
- South Carolina9 studies
- South Dakota3 studies
- Tennessee32 studies
- Texas53 studies
- Utah21 studies
- Virginia20 studies
- Washington30 studies
- West Virginia3 studies
- Wisconsin28 studies
Recently updated studies
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06976476Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06948084Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06465316A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Recruiting
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06055894Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06398457Limited-duration Teclistamab
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05932680Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 5, 2026 · NCT06904066Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Recruiting
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06630104A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07582432A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 1, 2026 · NCT06679829A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07589634A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05519085The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07850284A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07409246A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT04973605Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Sep 28, 2026 · NCT03412877Tissue Collection for Studies of Lymph Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT01676805A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 25, 2026 · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06052826From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.